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Abstract
Gemcitabine is a first-line agent for advanced pancreatic cancer therapy. However, its efficacy is often limited by its
poor intracellular metabolism and chemoresistance. To exert its antitumor activity, gemcitabine requires to be con-
verted to its active triphosphate form. Thus, our aim was to improve gemcitabine activation using gene-directed en-
zyme prodrug therapy based on gemcitabine association with the deoxycytidine kinase::uridine monophosphate
kinase fusion gene (dCK::UMK) and small interference RNA directed against ribonucleotide reductase (RRM2) and
thymidylate synthase (TS). In vitro, cytotoxicity was assessed by 3-[4,5-dimethylthiazol-2-yl]-3,5-diphenyl tetrazo-
lium bromide and [3H]thymidine assays. Apoptosis-related gene expression and activity were analyzed by reverse
transcription–polymerase chain reaction, Western blot, and ELISA. For in vivo studies, the treatment efficacy was
evaluated on subcutaneous and orthotopic pancreatic tumor models. Our data indicated that cell exposure to gem-
citabine induced a down-regulation of dCK expression and up-regulation of TS and RR expression in Panc1-resistant
cells when compared with BxPc3- and HA-hpc2–sensitive cells. The combination of TS/RRM2 small interference
RNA with Ad-dCK::UMK induced a 40-fold decrease of gemcitabine IC50 in Panc1 cells. This strong sensitization was
associated to apoptosis induction with a remarkable increase in TRAIL expression and a diminution of gemcitabine-
induced nuclear factor-κB activity. In vivo, the gemcitabine-based tritherapy strongly reduced tumor volumes and
significantly prolonged mice survival. Moreover, we observed an obvious increase of apoptosis and decrease of
cell proliferation in tumors receiving the tritherapy regimens. Together, these findings suggest that simultaneous
TS/RRM2-gene silencing and dCK::UMK gene overexpression markedly improved gemcitabine’s therapeutic activity.
Clearly, this combined strategy warrants further investigation.
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Introduction
Pancreatic adenocarcinoma is one of the most deadly forms of cancer.
With a 5-year survival rate of only 3% and a median survival of less
than 6 months, diagnosis of pancreatic adenocarcinoma is fatal for
patients. The tendency is for highly aggressive locoregional invasion
making curative surgery impossible [1]. Conventional chemotherapy
and radiotherapy, alone or in combination, have limited effect on
the overall survival of patients with pancreatic cancer [2]. Recently,
gemcitabine (2′,2′-difluorodeoxycytidine) has emerged as the first-
line treatment of locally advanced and metastatic pancreatic cancers
[3–5]. It is the treatment of choice as a single agent or in combina-
tion with other cytotoxic agents for solid tumors including ovarian,
non–small cell lung, and pancreatic cancers [6–8].
The antitumor activity of gemcitabine is exerted by its phosphory-
lated metabolites. After translocation across the cellular membrane by
nucleoside transporters [9], gemcitabine is phosphorylated to its mono-
phosphate (dFdCMP) form by the deoxycytidine kinase (dCK) in a rate-
limiting step. Then, other nucleoside kinases further phosphorylate
dFdCMP to its two active diphosphate and triphosphate (dFdCTP)
forms [10–12]. The dFdCTP competes with the natural deoxycytidine-
triphosphate analog for incorporation inDNAandRNA [13,14], causing
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masked chain termination [11,12], and inhibits CTP synthase. This ef-
fect blocks the de novo DNA synthesis pathway.
Unfortunately, despite its promising activity against cancer cells,
response rates to gemcitabine in pancreatic cancers remain low, with
less than 20% objective response in clinical cases [3–5]. After injec-
tion, gemcitabine is often confronted with poor phosphorylation to
its active triphosphate metabolite, rapid deactivation, and emergence
of chemoresistance. Insufficient intracellular concentration of dFdCTP
because of inefficient cellular uptake, reduced levels of gemcitabine ac-
tivation, or increased drug degradation can be cited among the nu-
merous mechanisms of resistance acquired during or after gemcitabine
treatment [15].
In the present study, we hypothesized that altered expression/
activity of enzymes directly involved in gemcitabine metabolism con-
stitutes an important form of chemoresistance. Deficiency in dCK
activity has been considered as one of the main mechanisms responsi-
ble for the development of resistance to gemcitabine. Several authors
have described a relationship between dCK activity and sensitivity to
gemcitabine in cells with acquired resistance to gemcitabine [16–18].
In this context, gene therapy may enhance gemcitabine metabolism
and, consequently, improve tumor cell responsiveness to this prodrug.
Some studies emphasizing the first limiting step of gemcitabine phos-
phorylation by overexpression of dCK in tumor cells deficient in
this enzyme have shown restoration of the sensitivity to gemcitabine
[15,19,20]. Moreover, gemcitabine phosphorylation can be improved
by uridine monophosphate kinase (UMK) overexpression. UMK phos-
phorylates CMP, UMP, and dCMP to their respective diphosphate
forms [21], and UMK has been shown to play an important role in
the activation of deoxycytidine analogs [22,23]. A fusion gene combin-
ing dCK with UMK was shown to be efficient in sensitizing hamster
pancreatic cancer cells to gemcitabine treatment [24].
In parallel, several data support the hypothesis that gemcitabine re-
sistance may also be dependent on ribonucleotide reductase (RR) and
thymidylate synthase (TS) overexpression [25,26]. Thus, small inter-
ference RNA (siRNA) targeting TS and RR can be of great interest
for specific TS and RR gene silencing. Recently, it was demonstrated
that RRM2 siRNA targeting the subunit responsible for RR activity
enhanced gemcitabine-induced cytotoxicity both in vitro and in vivo
[26,27]. Obviously, the concomitant inhibition of TS and RR expres-
sion would thus promote sensitization to gemcitabine in different ways,
including the reversal of dCK activity inhibition, and a competitively
higher incorporation of dFdCTP into DNA.
The purpose of the present study was to improve gemcitabine
efficacy by increasing gemcitabine anabolism, acting especially on
the dCK, TS, and RR enzymes. We investigated potential changes in
dCK, TS, and RR expression and examined whether gemcitabine
therapy improvement can be accomplished by an anticancer gene-
directed enzyme prodrug therapy (GDEPT) strategy that provides
enhanced dCK::UMK fusion gene expression associated with spe-
cific TS and RR gene silencing. To this end, an adenovirus express-
ing the dCK::UMK fusion protein and siRNA directed against TS
and RRM2 were used to favor conversion of gemcitabine into its toxic
phosphorylated metabolite and circumvent existing chemoresistance.
The effect of gemcitabine combination with Ad-dCK::UMK and
TS/RRM2 siRNA was assessed on cell survival and apoptosis both
in vitro and in vivo on subcutaneous and orthotopic pancreatic tu-
mor models.
The current study demonstrated that simultaneous dCK::UMK
overexpression and TS/RRM2 gene silencing significantly improved
the antitumor activity of gemcitabine. Furthermore, apoptosis seems
to be a major mechanism of the potent induced tumor cell death.
Materials and Methods
Cell Cultures
Human pancreatic cell lines BxPc3 and Panc1 from ATCC (LGC
Promochem, France), HA-hpc2 (developed in our laboratory from
human pancreatic metastasis), and human embryonic kidney AD293
cell line (Stratagene, France) were maintained at 37°C in a humid
atmosphere with 5% CO2. Panc1, HA-hpc2, and AD293 cells were
grown in Dulbecco’s modified Eagle medium–Glutamax medium,
whereas BxPc3 cells were grown in RPMI 1640–Glutamax. Media
were supplemented with 10% heat-inactivated fetal calf serum, peni-
cillin (100 U/ml), and streptomycin (100 μg/ml). All reagents were
purchased from Invitrogen (Cergy Pontoise, France).
Vector Constructs and Adenovirus Production
For the fusion gene dCK::UMK, the self-cleaving FMDV 2A pep-
tide was inserted between dCK and UMK (Cayla, Toulouse, France).
The cDNA corresponding to human dCK and dCK::UMK were
recovered by polymerase chain reaction (PCR) from pVIVOTKSh-
DCK and pVIVOTKSh-DU plasmids (Cayla), respectively, using spe-
cific primers. The PCR fragments were converted to blunt ends, and
their 5′ ends were phosphorylated with T4 polynucleotide kinase (New
England Biolabs, Ozyme, Saint Quentin en Yvelines, France). Each
insert was then ligated into the EcoRV site of pShuttle-CMV using
T4 ligase (New England Biolabs). Thereafter, the two recombinant
plasmids were grown in Escherichia coli strain DH5α and were used
to obtain the corresponding recombinant adenoviruses according to
Stratagene instructions. Briefly, the resulting clones were linearized
with PmeI and recombined with pAdEasy-1 in BJ5183-AD-1 bacteria.
Purified recombinant plasmids were linearized by PacI restriction
enzyme and subsequently transfected into the adenovirus E1 gene–
producing AD293 cells to create adenoviruses. Recombinant viruses
were propagated in AD293 cells, purified by CsCl step gradient ultra-
centrifugation, and tittered by standard methods [28,29].
siRNA Transfection
Tumor cells (70% of confluence) were transfected with 100 nM
of TS and/or RRM2 siRNA using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s protocol.
Expression Analysis
Analyses of gene expression were all performed after 48 hours of
gemcitabine treatment. Indeed, we have observed in preliminary experi-
ments that, whereas 72 hours of treatment were necessary to observe a
significant difference in cytotoxic effects, 24 to 48 hours of gemcitabine
treatment induced a significant gene expression.
Semiquantitative reverse transcription–PCR analysis. Total RNA
extractions were performed using TRIzol reagent (Invitrogen) and
treated with RNase-free Dnase I. Total RNA was reverse-transcribed
and amplified by PCR. Oligonucleotides used as PCR primers are
summarized in Table 1. Polymerase chain reactions for hENT1, dCK,
dCK::UMK, TRAIL, and Survivin genes were carried out as follows:
3 minutes at 94°C, followed by 30 cycles (40 seconds at 94°C, then
40 seconds at 55°C [dCK], 58°C [hENT1, dCK::UMK, and Survivin],
or 62°C [TRAIL], and 1 minute at 72°C) and a final extension step
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(7 minutes at 72°C). Thymidylate synthase amplification conditions
were as follows: 4 minutes at 94°C, 30 cycles (30 seconds at 94°C,
1 minute at 58°C, and 2 minutes at 72°C) and an extension step of
7 minutes at 72°C. For Bax and Bcl2 amplification, conditions were
as follows: 3minutes at 94°C and 30 cycles for 1minute at 94°C, 1min-
ute at 58°C and 60°C for Bax and Bcl2, respectively, and 1 minute
at 72°C and 10 minutes at 72°C. With regards to RR gene, PCR was
performed as indicated: 3 minutes at 94°C and 30 cycles for 1 minute
at 94°C, 40 seconds at 58°C, 1 minute at 72°C, and 7 minutes at 72°C.
For GAPDH, PCR was incubated as followed: 3 minutes at 94°C, then
1 minute at 94°C, 45 seconds at 60°C, and 45 seconds at 72°C, re-
peated 34 times, and finally 5 minutes at 72°C. The experiments were
repeated three times for each assay.
Western blot analysis. Cells were harvested, washed with ice-cold
PBS, and lysed with RIPA buffer (Sigma-Aldrich, France). Total pro-
tein concentration was measured using the bicinchoninic acid assay
kit (Sigma). Equal amounts of proteins were separated on NuPAGE
Novex 4% to 12% Bis-Tris gels (Invitrogen) and transferred onto
Hybond-P poly(vinylidene difluoride) membranes (Amersham Biosci-
ences, Les Ulis, France) using a BioRad semidry transfer system. Blots
were then probed overnight at 4°Cwith rabbit polyclonal anti–caspase-3
(1:2000),mousemonoclonal anti–poly(ADP-ribose)polymerase (PARP)
(1:250), or mouse monoclonal anti–β-actin (1:2000); all antibodies
were from Santa Cruz, Tebu-Bio, France. Immunoblots were developed
using enhanced chemiluminescence–enhanced chemiluminescence re-
agents after incubating with horseradish peroxidase–conjugated second-
ary antibodies.
Cell Proliferation and Cytotoxic Activity
[ 3H]Thymidine incorporation. Cells were seeded on 96-well
plates and allowed to adhere overnight. Then, cells were infected with
Ad-dCK or Ad-dCK::UMK (multiplicity of infection, 100) and/or
transfected with TS/RRM2 siRNA (100 nM). After 24 hours, cells
were further treated with different concentrations of gemcitabine
(Lilly, France) for 72 hours. To determine DNA synthesis level, 1 μl
of [3H]thymidine (1 μCi/ml; Amersham Biotechnologies, France)
was added to each well 24 hours before the end of treatment. The
next day, cells were washed with PBS, fixed in ice-cold 10% trichloro-
acetic acid, and lysed in 0.34N NaOH. The radioactivity incorporated
into the DNA was measured in triplicate by liquid scintillation spec-
trometry with a beta counter (Kontron, France).
MTTassay. Cell viability was evaluated using 3-[4,5-dimethylthiazol-
2-yl]-3,5-diphenyl tetrazolium bromide (MTT) test. After the treatment
period as indicated above, the incubation media were removed and ex-
changed with 100 μl of fresh media containing MTT (0.2 mg/ml),
and cells were incubated at 37°C for 3 hours. The media were removed,
and formazan crystals were solubilized with 150 μl of DMSO. Absor-
bance at 570 nm was measured in triplicate using a microplate reader
(BioRad, France).
Detection of Apoptosis
Hoechst staining. Cells were seeded in four-well plates at a density
of 2 × 105 cells per well. After treatment, cells were washed with PBS
and fixed in 4% paraformaldehyde during 1 hour at 4°C. Cells were
then stained with Hoechst reagent (1 μg/ml; Sigma) in a dark chamber
at room temperature for 1 hour and examined using excitation and
emission filters of 348 and 480 nm, respectively.
Caspase-3 activity. Treated cells were collected by centrifugation
and washed twice with PBS. Caspase-3 activity was detected using
caspase-3 colorimetric assay kit (R&D Systems, France). Cell pellets
were recovered in lysis buffer, and protease activity was measured by
a colorimetric reaction at a wavelength of 405 nm. Experiments were
performed in triplicate and repeated three times.
Nuclear Factor-κB Transcription Analysis
DNA-binding assay. Nuclear extractions were performed on treated
cells using EpiQuick Extraction Kit (Euromedex, Strasbourg, France).
They were subsequently submitted to the NoShift Nuclear Factor-κB
(NF-κB) transcription assay, a colorimetric assay–based alternative
to electrophoretic mobility shift assay, according to the protocol in-
structions (Novagen, VWR, France). For quantification of activity, op-
tical densities were measured at 450 nm with a microplate reader
(BioRad, France).
NF-κB promoter activity. Transcriptional regulation of the NF-κB
gene was determined using a NF-κB promoter/luciferase construct
(NF-κB-luc; kindly provided by Professor Shinichi Kawai, Toho
University School of Medicine, Tokyo, Japan). After plating overnight
in a 24-well plate, cells were transiently transfected with NF-κB-
luc plasmid (1 μg) using Lipofectamine 2000 reagent (Invitrogen).
The next day, tumor cells were submitted to the different treatments.
Thereafter, cells were harvested by gentle scraping, washed once in
PBS, and resuspended in appropriate lysis buffer for subsequent analy-
sis. Luciferase assays were performed according to the manufacturer’s
protocol (Promega, Charbonnières, France) using a luminometer
(LUMISTAR BM6).
Pancreatic Tumor Models
Animals. Six-week-old female nude mice were purchased from
Elevage Janvier (le Genest, France), housed in appropriate animal
care facilities during the experimental period, and handled following
the institutional guidelines required for animal experimentation.
Subcutaneous pancreatic tumor xenograft model. Mice were sub-
cutaneously inoculated in their interscapular region with BxPc3 (1 ×
107) or Panc1 (2 × 107) tumor cells. When tumors became palpable
(100 mm3), mice were randomly divided into seven groups (n = 8).
Mice received intratumoral injection of 1 × 109 plaque-forming units
Table 1. Sequences of Primers Used in RT-PCR.
Gene Forward Primer (5′-3′) Reverse Primer (5′-3′)
hENT1 gctgggtctgaccgttgtat ctgtacagggtgcatgatgg
DCK atggtaccgccaccatggccaccccg atgtcgactcacaaagtactca
dCK::UMK atggtaccgccaccatggccaccccg atgcggccgcttagccttccttg
TS aaacgtgtgttctggaaggg ccatatctctgtattctgcc
RR atgaaaacttggtcgagcgat tggcaatttggaagcccataga
TRAIL ctgagcaacgcagactcgctgtccac tccaaggacacggcagagcctgtgccat
Bax tgcttcagggtttcatccagg tggcaaagtagaaaagggcga
Bcl2 aatggcaacccatcctggca ttctcctggatccaaggctc
Survivin atgggtgccccgacg ctcaatccatggcagcc
GAPDH accacagtccatgccatcac tccaccaccctgttgctgta
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(PFUs) of Ad-dCK (G3) or Ad-dCK::UMK (G4 and G6) at days 10
and 17. In addition, they were intratumorally injected with TS and
RRM2 siRNA (each 100 μg; G5, G6, and G7) at days 12 and 19.
Gemcitabine (15 mg/kg) was injected intraperitoneally (IP) in G2 to
G6 groups three times during 1 week. Reverse transcription–PCR
(RT-PCR) experiments were performed on tumor biopsies obtained
from two mice per group. Tumors were measured with calipers in three
dimensions, twice a week for approximately 1 month. Tumor volumes
were calculated using the formula: v = π/6 × length × height × width.
Orthotopic pancreatic tumor xenograft model. Tumor cell implan-
tation was made under surgical sterile conditions. The abdomen was
cleaned with iodine solution, and a 1-cm midline incision was made
to expose the pancreas. Panc1 cells (2 × 107 in 100 μl of PBS) were
injected into the tail of the pancreas using a 30-gauge needle and a
1-ml disposable syringe. Abdominal wound was closed in two layers
with 6-0 nylon surgical suture. Tumors were allowed to grow, and mice
were then randomly assigned in five (G1-G5) treatment groups (n =
14). Mice received peritumoral injection of 1 × 109 PFU of Ad-dCK::
UMK (G3 and G5) at days 10 and 17. In addition, they were peritu-
morally injected with TS and RRM2 siRNA (each 100 μg; G4 and
G5) at days 12 and 19. Gemcitabine (15 mg/kg) was injected IP in
G2 to G6 groups three times during 1 week. Six mice per group were
killed at day 30, and pancreatic tumors were dissected. Volumes were
measured as described above, and tumors were then fixed in Boin’s so-
lution for subsequent histologic diagnosis and immunohistochemistry
analysis. The remaining animals were observed daily for survival.
Tumor morphology, immunohistochemical staining for Ki-67, and
terminal deoxynucleotidyl transferase–mediated nick end labeling.
Samples from tumor xenografts were dissected, fixed in Boin’s solu-
tion, and then paraffin-embedded. Sections of 5 μm were realized and
submitted to hematoxylin/eosin staining for morphologic examina-
tion, Ki-67 staining for proliferation study (Abcam, Paris, France), or
DeadEnd Fluorometric TUNEL System (Promega) for in situ apop-
tosis study.
Statistical Analysis
Results represent means ± SEM. Differences between groups were
examined for statistical significance with analysis of variance and/or
the Student-Newman-Keuls test. P < .05 indicated a statistically signifi-
cant difference.
Results
Chemosensitivity to Gemcitabine Differs in Pancreatic
Tumor Cells
First, we determined the sensitivity of human pancreatic cells to
gemcitabine using MTT assay. Cells were submitted for 72 hours to
a range of gemcitabine concentrations going from 0.01 to 100 μM.
HA-hpc2 cells showed the highest sensitivity to gemcitabine with a half
maximal inhibitory concentration (IC50) equal to 0.01 μM. BxPc3 and
Panc1 cells exhibited intermediate (IC50 = 2 μM) and low (IC50 =
40 μM) sensitivity, respectively (Figure 1A). Thus, we defined HA-
hpc2 and BxPc3 as sensitive tumor cells; and Panc1, as resistant tu-
mor cells. To investigate the improvement of gemcitabine antitumor
effect by TS/RRM2 siRNA and Ad-dCK::UMK combination strategy,
the rest of the study was performed on the Panc1-resistant cells. The
BxPc3, gemcitabine-sensitive tumor cells that are highly susceptible to
respond to the combined strategy, were used as positive control.
Variations in Gemcitabine Sensitivity Are Related to Its
Metabolic Gene Expression
Several studies have demonstrated that tumor cell resistance to
gemcitabine can be related to a defect of gemcitabine transport [30]
and especially to a deficit of the hENT1 predominant nucleoside
transporter. To verify this option, we determined the level of hENT1
expression and its correspondent activity in gemcitabine-treated and
-untreated BxPc3 and Panc1 cells. Our data showed that basal hENT1
messenger RNA (mRNA) levels were unexpectedly slightly more
marked in the Panc1-resistant cells (Figure 1B) and increased in both
cell lines after a 48-hour period of gemcitabine treatment. Thereafter,
to verify hENT1 involvement in gemcitabine cytotoxicity, hENT1-
related transport activity was inhibited using nitrobenzylthioinosine
(NBTI). Tumor cells were incubated with NBTI (10 and 100 nM) in
the presence of increasing concentrations of gemcitabine for 72 hours.
As indicated in Figure 1C , BxPc3 gemcitabine-related cell death was
inhibited in a dose-dependent manner. On the contrary, NBTI treat-
ment didn’t affect Panc1 cells viability. In parallel, we studied the expres-
sion of different gemcitabine-related metabolic genes. Whereas basal
expression of dCK was more important in HA-hpc2 and BxPc3 cells,
TS and RR expressions were higher in Panc1 cells (Figure 1D). After
a 48-hour period of gemcitabine treatment, the gene expression pro-
file remained unchanged in BxPc3 and HA-hpc2 and was, on the
contrary, emphasized in Panc1 with a more marked decrease of dCK
mRNA and an increase of RR and TS mRNA. Thus, Panc1 tumor cell
resistance to gemcitabine seems to be due, at least in part, to alteration in
drug metabolism.
Ad-dCK::UMK and TS/RRM2 siRNA Increase Gemcitabine
Cytotoxicity In Vitro
Considering the decrease of dCK expression, the dramatic in-
crease of TS, and, to a lower extent, the increase of RR expression
in Panc1 cells, an adenovirus overexpressing dCK::UMK and siRNA
targeting TS and RR genes were used to favor gemcitabine phosphor-
ylation. Infection of BxPc3 and Panc1 cells with Ad-dCK::UMK for
48 hours resulted in dCK and dCK::UMK overexpression, when
compared with noninfected control cells. In the same way, the endoge-
nous expression of RR and TS observed in the nontransfected control
cells was downregulated in cells treated with the appropriate siRNA for
48 hours (Figure 2A). Growth inhibition studies using [3H]thymidine
incorporation assay indicated that inhibition of DNA synthesis gen-
erated by gemcitabine was increased in BxPc3 and Panc1 cells pre-
infected with Ad-dCK::UMK (P < .001 vs gemcitabine-treated cells)
or pretreated with the combination of TS and RRM2 siRNA (P <
.001 vs gemcitabine-treated cells), particularly in Panc1 cells. This
more marked retardation of cell proliferation resulted in a better cyto-
toxicity of gemcitabine. Indeed, overexpression of dCK::UMK fusion
gene contributed to reduce approximately five and seven times the
gemcitabine IC50 in BxPc3 (P < .001 vs gemcitabine-treated cells)
and Panc1 (P < .001 vs gemcitabine-treated cells) cells, respectively.
Likewise, inhibition of TS/RR expression reduced gemcitabine IC50
from 2 and 40 μM to 0.5 and 5 μM, respectively, in BxPc3 (P < .001
vs gemcitabine-treated cells) and Panc1 cells (P < .001 vs gemcitabine-
treated cells; Figure 2B). The IC50 data of [
3H]thymidine incor-
poration assays seemed to be slightly lower than those described in
MTT assays. The observed discrepancy can be explained by the delay
640 Ad-dCK::UMK GDEPT and TS/RR siRNA in Chemogene Therapy Réjiba et al. Neoplasia Vol. 11, No. 7, 2009
between the time course of DNA synthesis arrest and the implementa-
tion of cell death mechanisms.
Ad-dCK::UMK and TS/RRM2 siRNA Treatments Favor
Gemcitabine-Induced Apoptosis and Are Mainly Associated
with an Increase of TRAIL Expression
Gemcitabine failure can be due to defects in apoptosis pathways.
Thus, we next examined whether association of Ad-dCK::UMK or
TS/RRM2 siRNA would influence the responsiveness of pancreatic
tumor cells to gemcitabine-induced apoptosis. Western blot analysis
revealed that the slight 85-kDa PARP cleavage product observed after
gemcitabine treatment per se was augmented in BxPc3 and Panc1 cells
pretreated with either Ad-dCK::UMK or TS/RR siRNA (Figure 3A).
Panc1 cells either infected with Ad-dCK::UMK or transfected with
TS/RRM2 siRNA presented an increase of gemcitabine-mediated
caspase-3 activation, 348 AU (P < .001 vs gemcitabine-treated cells)
and 375 AU (P < .001 vs gemcitabine-treated cells), respectively (Fig-
ure 3B). In addition, these increases of caspase-3 activity were more
important than those observed in the BxPc3-sensitive model, in which
gemcitabine-related caspase-3 activity was augmented from less than
150 to 275 AU (P < .01 vs gemcitabine-treated cells) in the pres-
ence of Ad-dCK::UMK overexpression and to 298 AU (P < .01 vs
gemcitabine-treated cells) after TS/RRM2 gene silencing. These re-
sults were confirmed by Western blot analysis as demonstrated by the
higher intensity of the cleaved forms of caspase-3 (Figure 3A). Caspases’
activity is regulated by the inhibitors of apoptosis proteins, which de-
termine them for degradation. Among these inhibitors, Survivin was
Figure 1. Pancreatic tumor cells sensitivity to gemcitabine. (A) Gemcitabine cytotoxicity. Panc1, BxPc3, and HA-hpc2 cells were treated for
72 hours with increasing concentrations of gemcitabine (0.01-100 μM). Cell viability was measured using MTT test and was presented as
a percentage of untreated cell control values. Each curve is representative of four experiments performed in triplicate. (B) Expression of
the hENT1 nucleoside transporter. Cells were untreated or treated with gemcitabine for 48 hours, and RNA was extracted and submitted
to RT-PCR analysis using specific primers for hENT1 and GAPDH housekeeping gene. (C) Role of hENT1 in gemcitabine transport. BxPc3
and Panc1 cells were treated simultaneously with gemcitabine and the hENT1 inhibitor NBTI (10 and 100 nM). Three days later, cell sur-
vival was evaluated by MTT assays. (D) Expression of dCK, RR, and TS. Tumor cells were untreated or treated with gemcitabine at IC50
concentrations, and mRNA levels were evaluated 48 hours later using semiquantitative RT-PCR with specific primers.
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increased in tumor cells receiving gemcitabine treatment, when com-
pared with untreated control cells. Pretreatment with either Ad-dCK::
UMK or TS/RRM2 siRNA resulted in an obvious inhibition of the
gemcitabine-related upregulated Survivin (Figure 3C).
We next looked for the involvement of the main mediators of ex-
trinsic and intrinsic apoptotic pathways. Hence, we examined whether
TRAIL and Bax expressions were modified in gemcitabine-induced
apoptosis. Preinfection with Ad-dCK::UMK or transfection with TS/
RRM2 siRNA resulted in an enhancement of TRAIL expression that
seems to be equivalent in BxPc3 and Panc1 cells. Conversely, a slightly
augmented Bax expression and a weak reduction of Bcl2 expression
were observed in such treated cells (Figure 3C).
Association of TS/RRM2 siRNA with Ad-dCK::UMK Promotes a
Maximal Increase of Gemcitabine Efficacy in Tumor Cell Cultures
To obtain an optimal efficacy of gemcitabine, we finally studied the
simultaneous use of Ad-dCK::UMK and TS/RRM2 siRNA. As ex-
pected, MTT assays showed that in tumor cells receiving concomi-
tantly Ad-dCK::UMK and TS/RRM2 siRNA, gemcitabine IC50 was
further reduced to 0.1 and 1 μM in BxPc3 and Panc1 cells, respectively
(Figure 4A). Gemcitabine at 1 μM caused 54% of cell death in Panc1
cells previously treated with Ad-dCK::UMK plus TS/RRM2 siRNA
(P < .001 vs gemcitabine-treated cells), whereas being not effective
when used alone. Treatment with either Ad-dCK::UMK (P < .05 vs
gemcitabine-treated cells) or TS/RRM2 siRNA (P < .01 vs gemcitabine-
treated cells) increased gemcitabine’s cytotoxic effect to a lower extent.
At the same concentration, gemcitabine induced 78% of cell death
in BxPc3 treated with Ad-dCK::UMK plus TS/RRM2 siRNA (P <
.001 vs gemcitabine-treated cells). However, this enhanced cytotoxic
effect of gemcitabine on BxPc3 cells was, nevertheless, near equivalent
to that obtained with Ad-dCK::UMK (P < .001 vs gemcitabine-treated
cells) or TS/RRM2 siRNA (P < .001 vs gemcitabine-treated cells) alone.
For apoptosis analysis, Hoechst staining demonstrated an augmentation
of nuclear shrinkage and chromatin condensation and fragmentation
(Figure 4B). ELISA experiments showed in both BxPc3-sensitive cells
and Panc1-resistant cells treated with the tritherapy a more marked
activation of caspase-3 (P < .001 vs gemcitabine-treated cells) that was
furthermore significantly higher than that generated by the association
of gemcitabine with either Ad-dCK::UMK (P < .01 vs gemcitabine +
Ad-dCK::UMK–treated cells) or TS/RRM2 siRNA (P < .001 vs gem-
citabine + TS/RRM2 siRNA–treated cells; Figure 4C ). Increase of
caspase-3 activity was confirmed by the higher levels of the two
caspase-3 cleaved isoforms of 17 and 20 kDa. In addition, we observed
an enhanced TRAIL expression and a higher inhibition of Survivin and
Bcl2 expression. Concerning Bax proapoptogene, a slightly enhanced
expression was observed with the combined treatment (Ad-dCK::
UMK + TS/RRM2 siRNA + gemcitabine; Figure 4D). Several authors
reported that gemcitabine-resistant cells exhibited high basal and in-
duced NF-κB activity [31]. Thus, we next wanted to determine the
involvement of NF-κB in the enhancement of gemcitabine efficacy by
the association Ad-dCK::UMK plus TS/RRM2 siRNA. The role of
NF-κB was thus ascertained using the NoShift NF-κB assay and a lucif-
erase reporter gene assay. As shown in Figure 5, gemcitabine alone
increased NF-κB activity particularly in Panc1 cells (P < .05 vs non-
treated cells). Interestingly, the combination of Ad-dCK::UMK plus
TS/RRM2 siRNA significantly reduced the gemcitabine-induced active
NF-κB (P < .001 vs gemcitabine-treated Panc1 cells).
In Vivo Experiments
Having shown that combined modalities using Ad-dCK::UMK
and TS/RR siRNA improve gemcitabine activation and effectiveness
in vitro, particularly in the chemoresistant Panc1 tumor cells, we next
examined in vivo efficacy using BxPc3 and Panc1 tumor xenograft
models in immune-deficient mice.
Combination of gemcitabine with Ad-dCK::UMK plus TS/RRM2
siRNA inhibits subcutaneous tumor xenograft growth. To deter-
mine a comparative efficacy of the tritherapy strategy on gemcitabine-
sensitive and -resistant tumor models, BxPc3 and Panc1 subcutaneous
tumor models were established. The treatment protocols were ini-
tiated with comparable tumor volumes in both BxPc3 and Panc1
tumor–bearing mice (approximately 100 mm3, as indicated in the
Figure 2. Combination of gemcitabine with Ad-dCK∷UMK or TS/
RRM2 siRNA improves gemcitabine cytotoxic apoptotic effect.
(A) Efficacy of recombinant adenovirus transduction and siRNA
transfection. BxPc3 and Panc1 cells were either infectedwith adeno-
viruses expressing dCK or dCK∷UMK or transfected with TS and/
or RRM2 siRNA. The RT-PCR analysis was carried out after a
48-hour treatment period on the total RNA using specific primers.
dCK, dCK∷UMK, RR, and TS expressions were compared with
untreated control cells. The nonspecific scramble (Sc) siRNA was
used as a negative control for siRNA. (B) Effect of Ad-dCK∷UMK
and TS/RRM2 siRNA on gemcitabine cytotoxicity. Cells were treated
as described above and further received increasing concentrations
of gemcitabine for 72 hours. In [3H]thymidine incorporation and
MTT assays, results of gemcitabine combined treatments are rela-
tive to Ad-dCK∷UMK, TS, and/or RR siRNA treatments. The aver-
age percentage values obtained in cells treated with gemcitabine
alone are relative to those of untreated cells. Values represent the
mean of four experiments performed in triplicate. Asterisks indicate
significant difference (*P < .05, **P < .01, and ***P < .001) ob-
served after the various combined treatments when compared with
gemcitabine alone.
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Materials and Methods section). First, to determine the efficacy of the
recombinant adenovirus transduction and siRNA transfer, we per-
formed RT-PCR experiments and analyzed the expression of the target
genes in tumor biopsies recovered at day 21. As shown in Figure 6A,
dCK::UMK fusion gene was highly expressed in tumor tissues obtained
from mice treated with Ad-dCK::UMK alone or combined to TS/
RRM2 siRNA. Expression of TS and RR genes was inhibited in biop-
sies from TS/RRM2 siRNA and TS/RRM2 siRNA plus Ad-dCK::
Figure 3. Combination of gemcitabine with Ad-dCK∷UMK or TS/RRM2 siRNA improves gemcitabine cytotoxic apoptotic effect.
(A) Enhancement of PARP and caspase-3 activation. To assess PARP and caspase-3 activation, Western blot analysis experiments were
performed on cell lysates obtained from cells treated with either Ad-dCK∷UMK or TS/RRM2 siRNA and further treated with gemcitabine
(IC50 doses) during 48 hours. The upper panels represent the 116-kDa native form and the 85 kDa activated form of PARP. The lower
panels illustrate the native and the cleaved forms of caspase-3 (17 and 20 kDa). (B) Quantitative measurement of caspase-3 activ-
ity. Caspase-3 activation was also evaluated by colorimetric assays. Data are representative of three independent experiments. Asterisks
indicate significant difference (**P < .01 and ***P < .001) observed after the various treatments when compared with gemcitabine
alone. (C) Expression study of different apoptotic genes. Treated cells were submitted to gemcitabine treatment for 48 hours and then
used for TRAIL, Bax, Survivin, and Bcl2 mRNA level measurement using RT-PCR analysis. GAPDH was used as an internal control.
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UMK–treated mice. Second, concerning the treatment efficacy, as ex-
pected, BxPc3 tumor model responded efficiently to gemcitabine (P <
.01 vs nontreated BxPc3-bearing mice), which was not the case of the
chemoresistant Panc1 tumor model (NS; Figure 6B). At the end of
the experiment, the concomitant association of Ad-dCK::UMK and
TS/RRM2 siRNA with gemcitabine reduced tumor volumes by 66%
and 78% (P < .001), respectively, in BxPc3 and Panc1 tumor models,
when compared with mice treated with gemcitabine alone. Further-
more, in comparison to the dual-therapy regimens, the tritherapy
generated 57% (P < .05) and 48% (P < .05) of Panc1 tumor volume
Figure 4. Maximal optimization of gemcitabine efficacy is obtained by combination with Ad-dCK∷UMK and TS/RR siRNA. (A) Cytotoxic
effect of Gemcitabine combination with Ad-dCK∷UMK and TS/RR siRNA. Cell viability was determined on Ad-dCK∷UMK–infected and/
or TS/RR siRNA–transfected cells by MTT assay after 72 hours of treatment with increasing concentrations of gemcitabine. The average
percentages of the MTT value obtained in gemcitabine-treated cells are relative to those of untreated cells. Concerning the gemcitabine
combined treatments, results represent relative value of gemcitabine-combined treatments to Ad-dCK∷UMK, TS/RR siRNA, or Ad-dCK∷UMK
plus TS/RR siRNA treatments. Data are the result of three independent experiments. Asterisks indicate significant difference (*P< .05, **P<
.01, and ***P< .001) observed after the various treatments when compared with gemcitabine alone. (B) Hoechst staining. Cells were treated
as indicated in the Materials and Methods section. Apoptotic cells were visualized using fluorescent microscope. (C) Caspase-3 activation.
Activity of caspase-3 was studied by Western blot analysis and colorimetric activity assay on cells having received Ad-dCK∷UMK plus
TS/RRM2 siRNA and further treated for 48 hours with gemcitabine at IC50 doses. Asterisks indicate significant difference (**P < .01 and
***P < .001) observed after cell treatment with gemcitabine associated to both Ad-dCK∷UMK and TS/RR siRNA treatments compared with
cells treated with gemcitabine plus Ad-dCK∷UMK or gemcitabine plus TS/RRM2 siRNA. (D) Expression of apoptotic mediators. In the same
experiment, TRAIL, Bax, Bcl2, and Survivin apoptotic gene expressions were evaluated by RT-PCR experiments using their respective specific
primers. The expression of GAPDH is shown as an internal control.
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diminution when compared with mice treated with gemcitabine plus
Ad-dCK::UMK and gemcitabine plus TS/RRM2 siRNA, respectively.
Importantly, in the mean time, these inhibitions were higher than those
observed in BxPc3-sensitive tumor model, in which 39% (NS vs gemci-
tabine + Ad-dCK::UMK–treated mice) and 31% (NS vs gemcitabine +
TS/RRM2 siRNA–treated mice) of tumor inhibition were observed.
Gemcitabine-based combination therapy delays tumor growth and
prolongs survival of mice bearing orthotopic pancreatic cancer xeno-
grafts. Taking in account the appropriate tumor microenvironment,
the in vivo investigation was extended to a much more predictive
orthotopic pancreatic cancer Panc1 model. Tumor extension was de-
termined by explorative laparotomy (n = 6) 30 days after tumor estab-
lishment. Figure 7A summarizes tumor growth evolution showing that
mice treated with gemcitabine alone have a mean tumor volume of
839 mm3 versus 1260 mm3 in control mice (33% reduction of tumor
growth, NS vs untreated control mice). Gemcitabine plus TS/RRM2
siRNA treatment reduced the tumor volume to 398 mm3, correspond-
ing to a mean 68% reduction of tumor volume (P < .01 vs gemcitabine-
treated mice). Treatment with gemcitabine plus Ad-dCK::UMK
resulted in a mean 65% reduction of tumor volume (446 mm3, P <
.01 vs gemcitabine-treated mice). As expected, mice having received
gemcitabine treatment combined with TS/RRM2 siRNA and Ad-
dCK::UMK demonstrated the greatest inhibition of tumor growth
and bore an average tumor volume of 151.02 mm3 resulting in a mean
82% decrease of tumor growth (P < .001 vs gemcitabine). Furthermore,
combined treatment significantly prolonged survival of mice. Half of
the mice receiving gemcitabine and Ad-dCK::UMK in combination
were alive and exhibited a healthy appearance. Moreover, combination
of TS/RRM2 siRNA to gemcitabine treatment prolonged survival of
mice by 62% (P < .01 vs gemcitabine-treated mice). The most im-
portant prolongation of survival was observed in mice treated with
gemcitabine combined to Ad-dCK::UMK and TS/RRM2 siRNA, with
seven of eight mice still alive at the end of 3 months of experiment (P <
.001 vs gemcitabine-treated mice; Figure 7D). Tumor tissues were sub-
jected to in situ apoptosis examination (Figure 7C). Terminal deoxy-
nucleotidyl transferase–mediated nick end labeling (TUNEL)–positive
cells were most prominent in tumor biopsies obtained from animals
Figure 5. Role of NF-κB in tumor cell sensitivity to gemcitabine alone or in combination with Ad-dCK∷UMK and TS/RRM2 siRNA. BxPc3
and Panc1 tumor cells were cotreated with Ad-dCK∷UMK and TS/RR siRNA. One day later, cells further received 2 and 40 μMof gemcitabine,
respectively, and NF-κB activation was studied after 48 hours. (A) NoShift NF-κB colorimetric assay. Cells were harvested, and NF-κB activity
was evaluated according to the manufacturer’s recommendations. (B) NF-κB luciferase gene reporter assay. Herein, cells were primary trans-
fected with a plasmid-expressing luciferase under control of an NF-κB response element. Luciferase assays were then performed according
to the manufacturer’s protocol. All experiments were performed in triplicate and repeated at least three times. Asterisks indicate significant
difference (**P < .01 and ***P < .001) observed in cells treated with the tritherapy gemcitabine plus Ad-dCK∷UMK plus TS/RR siRNA com-
paredwith cells treatedwithgemcitabine alone. *P<.05 indicates the significant differenceobservedbetweengemcitabine-treatedPanc1cells
relative to untreated Panc1 cells.
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treated with Ad-dCK::UMK and TS/RRM2 siRNA in combination
with gemcitabine, when compared with mice treated with gemcitabine
alone. Protease activity analyzed by Western blot showed that caspase-3
activation after exposure to gemcitabine was significantly increased in
tumors of mice receiving the combined treatment (data not shown).
No apoptosis was seen in healthy pancreas biopsies, in which no
caspase-3 cleavage was observed (data not shown). In addition, we evalu-
ated the tumor proliferative activity. As shown in Figure 7C , tumor
biopsies from mice treated with the “three-therapy” protocol have a re-
duced number of Ki-67–positive tumor cells in comparison to tumors
from gemcitabine-treated animals.
Discussion
The focus of the present work was to investigate the molecular
modulation of gemcitabine metabolism and to improve its antitumor
cytotoxic effect. Thus, to provide new insight into pancreatic cancer
treatment, we have performed a strategy combining GDEPT system
and siRNA-based methodology. Our approach was motivated by the
hypothesis that gemcitabine resistance may be dependent on de-
creased expression of dCK and/or overexpression of RR and TS. Re-
cent studies have reported that the ratio of expression of these genes
could be responsible for the acquired and inherent chemoresistance
of pancreatic cancer cells to gemcitabine [32].
In the current study, the sensitivity of different pancreatic tumor
cell lines to gemcitabine corroborated other data reported elsewhere
and characterized Panc1 and BxPc3 cells as resistant and sensitive
cells, respectively [33,34]. Nevertheless, variations of IC50 were ob-
served due to the different experimental conditions from laboratory
to another. In many studies, the proposed mechanisms of chemo-
resistance to nucleoside analogs are the low levels of proteins impli-
cated in drug transport or the dysregulation of intracellular enzymes
(e.g., kinases, deaminases, and nucleotidases) responsible for their
metabolism [15,21,26]. Thus, quite logically, we next attempted to
analyze gemcitabine transporters and especially the hENT1 trans-
porter, which deficiency was correlated to lack of gemcitabine transport
Figure 6. Overexpression of dCK∷UMK and down-regulation of TS/RR improved gemcitabine’s therapeutic effect in subcutaneous
pancreatic tumor models. Nude mice were subcutaneously inoculated with BxPc3 or Panc1 cells, and when their tumor size reached
100 mm3, they received intratumor injection of Ad-dCK∷UMK (1 × 109 PFU) ± TS/RR siRNA (100 μg). Gemcitabine (15 mg/kg body
weight) was administrated intraperitoneally. Control group was treated with 0.9% NaCl. (A) Ad-dCK∷UMK and TS/RR siRNA function-
ality. Tumors were recovered from two mice per group, and RT-PCR experiments were carried out to demonstrate the reduction of
endogenous TS and RR expression and the overexpression of dCK and dCK∷UMK after siRNA and Ad-dCK∷UMK treatments, respec-
tively. GAPDH was used as an internal control. (B) Tumor growth. Tumor growth evolution of BxPc3 and Panc1 tumors was followed up
by tumor volume measurement two times weekly. NS indicates not significant. **P < .01 and ***P < .001 versus control.
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and chemoresistance [30]. Our findings indicated that inhibition of the
hENT1-mediated transport by NBTI modestly modifies gemcitabine
activity on BxPc3 and does not alter gemcitabine cytotoxicity on the
resistant Panc1 cells. Furthermore, RT-PCR experiments demonstrate
augmentation of hENT1 expression after gemcitabine treatment in
both BxPc3 and Panc1 cells. Thus, BxPc3 and Panc1 sensitivity to
gemcitabine does not seem to involve the hENT1 transporter.
We next addressed the question concerning the modulation of the
expression of cellular enzymes involved in gemcitabine metabolism
and its correlation with chemoresistance mechanisms. It is well estab-
lished that gemcitabine phosphorylation by dCK is the rate-limiting
step of gemcitabine prodrug activation because dCK deficiency is criti-
cally involved in acquired resistance [16–18]. Several data showed a
clear correlation between dCK activity and sensitivity of human tumor
cells to gemcitabine. In this study, the basal dCK expression was sig-
nificantly lower in Panc1-resistant cells compared with BxPc3- or
HA-hpc2-sensitive cells and was further downregulated after exposure
to gemcitabine. To overcome this situation, reexpression of dCK in
drug-resistant tumor cells is generally realized. However, transfer of
dCK alone does not result in complete restoration of gemcitabine
sensitivity [19,20]. Thus, we considered that the design of a recom-
binant adenovirus expressing dCK::UMK fusion gene might be more
efficient for pancreatic tumor chemosensitization to gemcitabine. As
expected, we demonstrated that dCK::UMK expression resulted in a
more marked increase of cell sensitivity to gemcitabine than did re-
expression of dCK alone. These data were illustrated by the significant
inhibition of DNA synthesis and cytotoxic effects. We demonstrated
that the designed Ad-dCK::UMK reduced six and eight times gemcita-
bine IC50, respectively, in BxPc3 and Panc1 cells. In addition, regarding
gemcitabine metabolism and tumor sensitivity, transcriptome analysis
also suggested the predictive value of RR and TS in chemoresistance
mechanisms. In fact, there is accumulating data indicating the correla-
tion between clinical response and dCK, TS, and RR gene expression
levels in treated patients [27,32,35]. In the present study, we showed
that gemcitabine treatment induced a strong increase of RR and TS ex-
pression in Panc1-resistant tumor cells and, at the same time, no signifi-
cant modification in BxPc3 and HA-hpc2. Thus, the increase of TS
and RR expression could be responsible, at least in part, for the low
Figure 7. Inhibition of orthotopic tumor formation and increased survival of tumor-bearing mice after combined gemcitabine-based treat-
ment. Thirty days after the beginning of treatment, six mice from each group (n = 14) were killed; their pancreatic tumors were recovered.
(A) Tumor growth. Recovered biopsies were measured in three dimensions. Asterisks indicate significant difference (**P< .01 and ***P<
.001) observed after gemcitabine combined treatments compared with gemcitabine alone. (B) Macroscopic findings of pancreas. Photo-
graphs represent excised pancreatic tumor from untreated mice and those receiving tritherapy protocol. (C) Representative immuno-
histochemistry examination. Biopsies were subsequently submitted to hematoxylin-eosin staining (left panels), TUNEL staining (middle
panels), and Ki-67 staining (right panels). (D) Kaplan-Meier survival curve. Remaining mice were followed for survival curve determination.
Results were analyzed statistically by log-rank test. Asterisks indicate significant difference (*P < .5, **P< .01, and ***P < .001) observed
after gemcitabine combined treatments compared with gemcitabine alone.
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response of Panc1 tumor cells to gemcitabine treatment. Augmentation
of TS expression is not surprising because experimental and clinical
studies observed an induction of TS expression after exposure to TS
inhibitors, a process that leads to the development of cellular drug re-
sistance to these agents [36]. On the basis of these findings and others
reported elsewhere, we attempted to block TS and RR expression using
TS/RRM2 siRNA. We observed that TS/RRM2 gene silencing was
associated with an increase of the cytotoxic effect induced by gemcita-
bine. It seems that TS/RRM2 siRNA were as effective as Ad-dCK::
UMK at reducing gemcitabine IC50 as indicated by the statistical analy-
sis realized in comparison to gemcitabine treatment. These findings
confirmed clearly the crucial role of TS and RR in gemcitabine chemo-
therapy efficacy. Moreover, it was reported that inhibition of TS and
RRM2 expression might result in a stimulation of dCK activity that
may be consistent with feedback activation in response to inhibition
of DNA synthesis and DNA damage [37].
Thus, ultimately to reinforce its metabolism and to optimize as
much as possible its antitumor activity, gemcitabine was used in com-
bination with Ad-dCK::UMK and the specific TS/RRM2 siRNA.
Combination of these two therapeutic strategies based on gene therapy
led to a 40-times decrease of gemcitabine IC50 in Panc1 cells (1 vs
40 μM in Panc1-nontreated cells), in comparison with the 7- and
8-times decrease obtained after combination of gemcitabine with
Ad-dCK::UMK and TS/RRM2 siRNA treatments, respectively. Al-
though Panc1 cells still remained more resistant than BxPc3 cells
(gemcitabine IC50 equal to 1 μM in Panc1 cells vs 0.1 μM in BxPc3
cells), diminution of gemcitabine IC50 generated by the tritherapy
was superior to that obtained in BxPc3-sensitive cells (a 20-fold de-
crease of IC50).
Several studies have provided evidence that chemotherapeutic
agents induce apoptotic tumor cell death. Recent findings suggest
that diminished apoptosis plays an important role in the resistance of
tumor cells to anticancer agents [38,39]. Few studies described the
comprehension of gemcitabine-related apoptosis, and little is known
about the apoptotic mediators involved in gemcitabine cytotoxic effect.
So, in the current study, in attempting to verify any correlation between
tumor chemosensitization to gemcitabine and apoptosis induction, we
looked for the involvement of some of the main mediators of both
extrinsic and intrinsic apoptotic pathways. Our data demonstrate that
combination of gemcitabine with the two other strategies induced a
significant increase of PARP cleavage and caspase-3 activation com-
pared with gemcitabine alone. This augmented activity of caspase-3
may be explained by diminution of the Survivin inhibitor of apop-
tosis protein expression, which was near completely inhibited in Panc1-
resistant tumor cells. In the same way, the combined treatment was
associated with decrease of the antiapoptotic mediator Bcl2 expression
and augmentation of Bax expression. Concerning the death receptor
pathway, the contribution of the Fas/FasL death receptor pathway in
gemcitabine-induced apoptosis has been a subject of controversy
[40,41]. To gain further insight into the mechanisms by which the tri-
therapy promotes apoptosis, we investigated the TRAIL ligand pathway.
It was already demonstrated that combination of TRAIL gene therapy
and chemotherapy has proved to be effective against various cancer dis-
eases [42,43]. Our finding indicated that tumor cell sensitization to
gemcitabine with Ad-dCK::UMK, TS/RRM2 siRNA, or both resulted
in a critical enhancement of TRAIL expression. These data suggest that
the improved tumor cell sensitization to gemcitabine involved TRAIL
contribution for apoptosis induction. Finally, another apoptotic path-
way that could be involved in gemcitabine chemoresistance is NF-κB
pathway. In fact, previous reports have demonstrated that constitutive
NF-κB activity is present in approximately 70% of human pancreatic
cancer and several pancreatic carcinoma cell lines [31,44–46]. Herein,
we confirmed the involvement of NF-κB activity in the tumor cell’s
resistance to gemcitabine. Moreover, the efficacy of the tritherapy proto-
col was showed to occur through a reduction of the gemcitabine-related
induction of NF-κB transcriptional activity. Future studies on the role
of apoptosis signaling molecules in pancreatic cancer chemosensitization
and treatment efficacy need more investigation.
To validate the results of in vitro experiments, subcutaneous and
orthotopic xenograft pancreatic cancer models were initiated in athymic
mice. In the subcutaneous tumor models, the simultaneous associa-
tion of Ad-dCK::UMK overexpression and TS/RRM2 gene silencing
enhanced BxPc3 and Panc1 tumor sensitivity to gemcitabine in a higher
way than did Ad-dCK::UMK or TS/RRM2 siRNA alone. This com-
bined treatment sensitizes the resistant Panc1 tumor model, as well as
the BxPc3-sensitive model to gemcitabine, indicating that our tri-
therapy is applicable to both resistant and sensitive tumor models.
Furthermore, mice treated with TS/RRM2 siRNA alone demonstrated
a nonsignificant therapeutic effect, thus indicating that the antitumor
effect observed in TS/RRM2 siRNA plus gemcitabine–treated mice
was actually related to gemcitabine. The in vivo tumor therapy study
using the Panc1 orthotopic pancreatic tumor model demonstrated that
tumor sensitization to gemcitabine by simultaneous treatment with
Ad-dCK::UMK and TS/RRM2 siRNA resulted in a significant reduc-
tion of tumor growth. All animals had statistically significant tumor
volume inhibition, with one third of animals showing complete tumor
regression. The survival of mice receiving this combined therapy proto-
col was improved. Tumor biopsies from mice receiving simultaneous
administration of gemcitabine and Ad-dCK::UMK plus TS/RRM2
siRNA presented increased apoptotic cells as determined by tumor
TUNEL analysis and a low number of proliferating cells. The dramatic
reduction of tumor growth may involve a bystander effect due to in-
tercellular transfer of active and/or inactive gemcitabine through trans-
porters. It may also involve transfer of apoptotic signals and notably
the TRAIL ligand that will attach to corresponding receptors on neigh-
boring cells. Indeed, although it is not fully understood which signals
are involved in these important processes, it has been suggested that
metabolites specifically generated in dying cells such as uric acid [47]
or apoptotic metabolites that are activated during apoptosis could be
transferred for bystander death [48]. Results were all the more interest-
ing; as gemcitabine was administered IP after a relative low-dose schedule
(15 mg/kg three times for 1 week) compared with the conventional
higher used doses reported in the literature (45-380 mg/kg) [49].
Nevertheless, hepatotoxicity of the therapeutic regimens was assessed.
Results demonstrated only a slight nonsignificant variation of aspartate
aminotransferase, alanine aminotransferase, and bilirubin levels in the
combined group compared with the gemcitabine-treated group (data
not shown).
Taken together, our finding suggest for the first time that com-
bined gemcitabine with TS/RR siRNA and dCK::UMK–based gene
therapy may indeed provide a chance to treat both gemcitabine-
sensitive and gemcitabine-resistant pancreatic tumors that are rela-
tively refractory to conventional gemcitabine treatment.
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